

found to be unprepared to deal with this new, unknown disease. Despite the reaction of the scientific world is planetary with more than 2000 trials started in a few months, so far there are neither specific treatments nor vaccines. The virus and its effects remain unknown and shrouded in mystery. There is not a clear enemy to combat such as a coronary plaque or a leaking or stenotic valve (Figure 1). Psychologically, the unknown generates fear and anxiety. It follows that perception of the COVID-19 pandemic is worse than that of CVD although the consequences and the number of victims between the 2 are incomparable.

The COVID-19 outbreak, often concentrated in limited areas, has rapidly transformed individual undertakings to a mass scenario which is communicated daily in numbers of infected or deaths on television and social media with the result that everybody has lost sight, significance, and importance of every single death within an epidemiological forest of numbers. In front of this, the medical-scientific world remains stunned. It implodes, with a lack of ideas on how to react. The defence strategy consists of *hiding* and shutting down society, despite the knowledge that this cannot last, and the price might be even higher than the disasters caused by the virus which, in any case, are significantly less than those of other epidemics, as the one of CVD. However, CVD does not reach the interest of the media. We are simply used to it.

## Two epidemics at the same time are too much: the collateral damage

Emphasis on COVID-19 has created concerns about contracting the infection during a hospital stay, ultimately causing a series of collateral damages.<sup>4</sup> This is true for all diseases, but particularly so for CVD and more specifically, for acute coronary syndromes (ACS), a time-dependent pathology.

All over Europe and the USA, during the early days of the epidemic, fewer patients reached the hospitals for ACS and... ACS were not prevented by the coronavirus, despite the proposal that the lockdown had results in less stress and therefore, less ACS or infarcts. This is not

true, actually, the opposite may be true: less exercise, fewer laboratory, or other tests and probably more weight gain is likely to increase rather than decrease ACS during a lockdown.

But, more than anything else, the anxiety generated by the *unknown* and the fear of acquiring SARS-COV-2 infections in the hospitals has prevented patients from seeking effective medical interventions, compromising CV care. The results are more sudden cardiac death, more complications of acute myocardial infarction (*often experienced at home*), more heart failure, and, eventually, more deaths.<sup>5,6</sup> Therefore, actually, the COVID-19 outbreak has negatively affected CVD by shifting the attention of patients like Mr Brown from his coronary problems to those related to the new coronary virus. Sorry *corona* not *coronary* virus! This is where the confusion lies.

**Conflict of interest:** Prof R. Ferrari reports personal fees from Servier International, grants and personal fees from Novartis, personal fees from Merck Serono, personal fees from Boehringer Ingelheim, personal fees from Sunpharma, personal fees from Lupin, personal fees from Doc Generici, personal fees from Pfizer, personal fees from Spa Prodotti Antibiotici, outside the submitted work; and Director of Art Research and Science S.r.l. (A.R.S.1). Prof C. Rapezzi reports personal fees from NOVARTIS, personal fees from ALNYLAM, personal fees from AKCEA, personal fees from SANOFI, grants from PFIZER, outside the submitted work. Dr P. Cimaglia as nothing to disclose.

## References


- Ferrari R, Pavasini R, Camici PG, Crea F, Danchin N, Pinto F, Manolis A, Marzilli M, Rosano GMC, Lopez-Sendon J, Fox K. Anti-anginal drugs-beliefs and evidence: systematic review covering 50 years of medical treatment. *Eur Heart J* 2019;**40**:190–194.
- Ferrari R, Ferrara I. Introduction: why and how do cardiologists need to take an interest and lead prevention programmes? *Eur Heart J* 2017;**38**:3255–3257.
- Ferrari R, Di Pasquale G, Rapezzi C. 2019 CORONAVIRUS: what are the implications for cardiology? *Eur J Prev Cardiol* 2020;**27**:793–796.
- Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. *JAMA* 2020;**323**:1775–1776.
- Baldi E, Sechi GM, Mare C, Canevari F, Brancaglione A, Primi R, Klersy C, Palo A, Contri E, Ronchi V, Beretta G, Reali F, Parogni P, Facchin F, Bua D, Rizzi U, Bussi D, Ruggeri S, Oltrona Visconti L, Savastano S. Out-of-hospital cardiac arrest during the Covid-19 outbreak in Italy. *N Engl J Med* 2020;**383**:496–498.
- De Rosa S, Spaccarotella C, Basso C, et al Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era. *Eur Heart J* 2020;**41**:2083–2088.



Roberto Ferrari MD  
Corresponding author  
Chair of Cardiology, Azienda  
Ospedaliero-Universitaria di Ferrara,  
Ospedale di Cona, Via Aldo Moro 8,  
44124 (Cona), Ferrara, Italy.  
Centro Cardiologico Universitario di Ferrara,  
Maria Cecilia Hospital, Cotignola (RA), Italy  
Email: fr@unife.it  
Telephone: +39 0532 239882



Prof. Claudio Rapezzi  
Centro Cardiologico Universitario di Ferrara,  
University of Ferrara, Ferrara, Italy.  
Maria Cecilia Hospital, Cotignola (RA), Italy



Dr Paolo Cimaglia,  
Maria Cecilia Hospital,  
Cotignola (RA), Italy

doi:10.1093/eurheartj/ehaa918

# Heart Failure 2019

## Insights From the National Society of Cardiology Journals

### Introduction

Most studies on heart failure (HF) management published in 2019 by high-ranking impact factor international journals focus on drug therapy.

This included administration of sacubitril-valsartan with initiation during the index admission and the benefits of SGLT2 inhibitors in reducing cardiovascular mortality and HF. Most of these studies, targeting a broad readership, fail to characterize important local issues.

Improvement in HF management needs to take into account specificities from different European Society of Cardiology (ESC) member countries. This approach may be achieved and disseminated to cardiologists by the National Society of Cardiology Journals (NSCJ). During the ESC Congress 2019, the ESC Editors' Network started an initiative intended to boost dissemination of cardiology research published in the NSCJ by summarizing in a review paper the evidence gathered in selected areas. The ESC Editors Network members decided the first topic of such a review to be publications in the field of HF.

## Epidemiology

Inequalities in the prevalence of risk factors, cardiovascular disease burden, cardiovascular mortality, and implementation of some therapeutic methods (coronary interventions, device implantations, and cardiac surgery) among the ESC member countries have recently been shown in the ATLAS study. These shortcomings depend on socio-economic factors and affect more predominantly middle-income than high-income countries. In a single-centre observational study of 1006 patients admitted to a coronary care unit in Egypt, Badran *et al.*<sup>1</sup> estimated the prevalence of HF by gender and preserved or reduced left ventricular ejection fraction (LVEF). They reported a higher prevalence of HF and a higher incidence of HF with reduced ejection fraction (HFrEF) among women. Female patients were older, more likely to be obese, with more co-morbidities, had less acute coronary syndromes and required fewer coronary interventions, but had a prognosis similar to men.

Nationwide information on mortality and readmissions in HF patients is also of interest. A retrospective analysis from Spain aimed to identify factors associated with in-hospital mortality and readmissions in 77 652 HF patients.<sup>2</sup> In-hospital mortality was 9.2%, rising to 14.5% at 1 year. The 1-year cardiovascular readmission rate was 33%. Risk factors associated with mortality were stroke, metastatic cancer, cardiorespiratory failure, shock, and acute myocardial infarction. Risk-standardized mortality rates were lower among patients discharged from high-volume hospitals. Importantly, the availability of a cardiology department at the hospital was associated with better outcomes.

## Specific causes of heart failure

Calcific aortic valve disease (CAVD) is a common disorder which may progress while remaining clinically unrecognized. However, the progression mechanisms remain unknown. In a single-centre study from Bulgaria, Tomova *et al.*<sup>3</sup> tested the hypothesis that the polymorphism rs10455872 at the lipoprotein (a) (Lp(a)) gene locus increases the risk of CAVD. In a comparison of 108 CAVD patients with 38 controls, they reported that the presence of  $\geq 1$  mutant allele of the gene was associated with a four-fold greater risk for CAVD. A report from the *Austrian Journal of Cardiology* by Kauffmann *et al.*<sup>4</sup> demonstrated that the diagnosis of transthyretin-amyloidosis has recently improved significantly with structural screening by magnetic resonance imaging (MRI). The coexistence of CAVD and transthyretin-amyloidosis has substantial implications. The study suggested the value of the electrocardiogram, echocardiography, MRI, technetium radionuclide imaging, and endomyocardial biopsy in these patients.<sup>4</sup> Subclinical myocardial involvement is common in systemic sclerosis (SSc) and is associated with HF and a worse prognosis. In a study of 73 SSc patients from Hungary, Vertes *et al.*<sup>5</sup> tested the 2D-speckle-tracking-derived global longitudinal strain (GLS) for the detection of early myocardial involvement.

Lower GLS values were found in patients compared with gender- and age-matched healthy controls. GLS values correlated with the duration of the disease from the onset of Raynaud's phenomenon, from the first non-Raynaud symptoms, and with the New York Heart Association (NYHA) functional class.

## Pathogenesis

In a prospective Russian study including 297 patients, Lelyavina *et al.*<sup>6</sup> reported the potential for differentiation, regeneration, and growth of satellite skeletal muscle precursor cells obtained from patients with HFrEF. The studied parameters were similar to those found in healthy donors. This may explain why walking  $> 1.5$  h/day induces more physiological reverse myocardial remodelling than aerobic training.

## Diagnosis

In another Russian study, Vdovenko *et al.*<sup>7</sup> compared 80 patients (NYHA Class I-IIa) with chronic HFpEF with 30 healthy controls by using the 6-minute walk-test and echocardiography. All patients had diastolic dysfunction (60 abnormal relaxation patterns and 20 pseudo normal patterns) with reduced global and segmental LV strain. The impact of HF on other body organs has been analysed by Içen *et al.*<sup>8</sup> from Turkey assessing liver stiffness (LS) in HF patients. Liver stiffness estimated using an ElastPQ technique was increased in patients with more advanced NYHA class. A higher LS was associated with higher right ventricular myocardial performance index, regurgitation pressure gradient, NT-proBNP, and aspartate aminotransferase levels. Assuming that the SYNTAX score is not just a measure of the severity but also the complexity of coronary artery disease Öztürk *et al.*<sup>9</sup> analysed the degree of coronary atherosclerosis, estimated by SYNTAX score and myocardial viability in Turkish patients with ischaemic cardiomyopathy. Patients without viability had a significantly higher SYNTAX score compared with those with viable myocardium.

## Treatment

Clinical implications of HF associated with valvular heart disease has been reported by several NSCJ. Transcatheter aortic valve implantation (TAVI) is an alternative to surgical aortic replacement for symptomatic severe aortic stenosis. Indications are now rapidly expanding towards patients at lower surgical risk. Generalization of the transfemoral vascular approach, technological advances, and increased operator skills have resulted in higher rates of procedural success and improved long-term survival. However, data on the incidence of readmission for HF after successful TAVI are scarce.

A French study on 1139 patients, by Guedeney *et al.*<sup>10</sup> reported that readmission for HF occurs in 1/10 patients after TAVI and suggests a strong risk factor for mortality. The main risk factors for HF readmission were LVEF  $\leq 35\%$ , chronic pulmonary disease, chronic kidney disease, diabetes, and atrial fibrillation. Along with international multicentre trials on the percutaneous mitral repair of functional mitral regurgitation associated with HF, national registries provide valuable real-life results in unselected patients which may inform clinical decision making at a local level.

Benak *et al.* reported a cohort of 30 MitraClip implantations in Czech patients with dilated cardiomyopathy and severe functional mitral regurgitation. Procedural success was 97% with no 90-day mortality. At 1 year, significant improvements in functional class, and quality of life scores were reported, associated with a reduction of LV

myocardial mass, an increase in systolic and diastolic arterial pressure and a mortality rate of 10%.

## Conclusion

Instead of publications in high-ranking impact factor international journals, NSCJ cover a wide spectrum of diagnostic and therapeutic modalities taking into account the national specifics of HF. In contrast, studies published in NSCJ are often single-centre and observational. However, information on HF strategies at a national level are useful in implementing ESC clinical practice guidelines and in optimizing HF patients' care.

**Conflict of interest:** none declared.

Plamen Gatzov MD\*, Jean-Jacques Monsuez MD, Gergely Agoston MD, Michael Aschermann MD, Hala Mahfouz Badran MD, Ariel Cohen MD, Kurt Huber MD, Evgeny Shlyakhto MD, Dilek Ural MD, Ignacio Ferreira-Gonzalez MD, Fernando Alfonso MD

Plamen Gatzov (Editor-in-Chief of Bulgarian Cardiology Journal), Bulgaria; Spain; Jean-Jacques Monsuez (Editor-in-Chief of Archives des Maladies du Cœur et des Vaisseaux Pratique), France; Gergely Agoston (Editor-in-Chief of Cardiologia Hungarica), Hungary; Michael Aschermann (Editor-in-Chief of Cor et Vasa), Czech Republic; Hala Mahfouz Badran (Editor-in-Chief of Egyptian Heart Journal), Egypt; Ariel Cohen (Editor-in-Chief of Archives of Cardiovascular Diseases) France; Kurt Huber (Editor-in-Chief of Austrian J Kardiologie), Austria; Evgeny Shlyakhto (Editor-in-Chief of Russian Journal of Cardiology), Russia; Dilek Ural (Editor-in-Chief of Archives of The Turkish Society of Cardiology), Turkey; Ignacio Ferreira-Gonzalez (Editor-in-Chief of Revista Española de Cardiología) Spain; Fernando Alfonso (Chairman of The Editors Network of the European Society of Cardiology), Spain.

\* Address for correspondence: Prof. Plamen Gatzov, MD, PhD, DSc, FESC, Medical University of Pleven, 1, St. Kl. Ohridski Street, 5800 Pleven, Bulgaria. Email: plamengatzov@yahoo.com

## References

1. Badran HM, Elgharably MA, Faheem N. Clinical characteristics and in-hospital outcome of heart failure in women: a single center registry from Egyptian cardiac care unit. *Egypt Heart J* 2019;**71**:167.
2. Martínez Santos P, Bover Freire R, Esteban Fernández A, Bernal Sobrino JL, Fernández Pérez C, Elola Somoza FJ, Macaya Miguel C, Vilacosta I. In-hospital mortality and readmissions for heart failure in Spain. A Study of Index Episodes and 30-Day and 1-year Cardiac Readmissions. *Rev Esp Cardiol (Engl Ed)* 2019;**72**:998–1004.
3. Tomova V, Alexandrova M, Atanasova M, Rashev T, Cekova M. The polymorphism RS10455872 at the lipoprotein (a) gene locus enhances the risk of aortic valve disease. *Bulg Cardiol J* 2019;**4**:45–50.
4. Kaufmann CC, Hennenberg J, Bonderman D, Kriz R, Koch J, Huber K, Jäger B. Transthyretin amyloidosis – update 2019. *Austr J Kardiol* 2019;**26**:112–116.
5. Vertes V, Nogradi A, Porpacz A, Minier T, Czirjak L, Komocsi A, Faludi R. Left ventricular global longitudinal strain is impaired in systemic sclerosis and shows a significant correlation with the functional capacity of the patients. *Cardiol Hung* 2019; **49**:12–16.
6. Lelyavina TA, Sitnikova MY, Galenko VL, Kozlov PS, Bortsova MA, Demchenko EA, Ganenko OS, Golovkin AS, Kostareva AA, Dmitrieva RI. The role of muscle tissue in the pathogenesis of chronic heart failure—the potential of exposure (FORMA study). *Russ J Cardiol* 2019;**2**:58–65.
7. Vdovenko DV, Libis RA. Assessment of the functional state of left heart in patients with chronic heart failure with preserved ejection fraction. *Russ J Cardiol* 2019;**2**:26–30.
8. Içen YK, Demirtas AO, Koç AS, Sumbul HE, Koc M. Liver stiffness value obtained with ElastPQ ultrasound increases with NYHA class in chronic heart failure patients and reduced ejection fraction. *Turk Kardiyol Dern Ars* 2019;**47**:281–283.
9. Öztürk S, Gürbüz AS, Kirma C. Relationship between SYNTAX score and myocardial viability in ischemic cardiomyopathy. *Turk Kardiyol Dern Ars* 2019;**47**:350–356.
10. Guedeney P, Huchet F, Manigold T, Rouanet S, Balagny P, Leprince P, Lebreton G, Letocart V, Barthelemy O, Vicaut E, Montalescot G, Guerin P, Collet J-P. Incidence of risk factors for and impact of readmission for heart failure after successful transcatheter aortic valve implantation. *Arch Cardiovasc Dis* 2019;**112**:765–772.

doi:10.1093/eurheartj/ehaa832

# The right ventricle in COVID-19 patients

## A forgotten essential chamber that may be involved in the cardiac complications of COVID-19

The right ventricle seems to have been forgotten among heart chambers, although some studies have shown its crucial role in coronavirus disease 2019 (COVID-19). Interestingly, both its size and function are believed to be associated with cardiac complications and mortality in COVID-19.

COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which spread globally after the first case was observed in Wuhan at the end of 2019.<sup>1</sup> Recent studies suggested that COVID-19 may be accompanied by cardiac complications, including acute coronary syndrome, cardiac arrhythmia, myocarditis, pericarditis, and heart failure in nearly 20% of patients, which are associated with an increased risk of mortality.<sup>2</sup> Laboratory data such as cardiac troponin as well as echocardiography parameters can be effective means of cardiac assessment in these patients. Transthoracic echocardiography (TTE) is the optimum method of cardiac imaging used in COVID-19 patients which is able to diagnose different cardiac abnormalities

including haemodynamic dysfunction. Also, it is useful for the prediction of future cardiac morbidity in these patients.<sup>3</sup>

Reduced right ventricular (RV) activity is a good predictor for heart failure and cardiac mortality.<sup>4</sup> The effect of COVID-19 on the right ventricle activity is in the main unknown. It seems that the pathophysiological pathways of COVID-19 including increased afterload after acute respiratory distress syndrome, pulmonary embolism, cytokine-negative inotropic effects, and renin–angiotensin system dysfunction are possible mechanisms for RV dysfunction in COVID-19 patients.<sup>5</sup> A summary of some studies which have been conducted to assess RV function in COVID-19 patients is presented in Table 1.

Li *et al.* performed an echocardiographic investigation in 120 cases of COVID-19. They assessed RV fractional area change, tricuspid annular plane systolic excursion, and Doppler tricuspid tissue annular velocity. In their study, RV function was categorized by right ventricular longitudinal strain (RVLS). It was concluded that patients with the